Rehabilitation for older Veterans recovering from long-COVID
Evaluating the Long-term Health Consequences of COVID-19 and Rehabilitation Therapies to Speed Convalescence
This study is testing whether a new treatment can help older Veterans with long-COVID feel better by improving their blood vessel health and reducing fatigue and cognitive issues.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | VA Office of Research and Development Federal |
| Locations | 1 site (Salt Lake City, Utah) |
| Trial ID | NCT05373043 on ClinicalTrials.gov |
What this trial studies
This study aims to improve the health outcomes of older Veterans suffering from long-COVID by developing rehabilitation therapies that enhance vascular endothelial function. The approach focuses on addressing oxidative stress and inflammation, which are exacerbated by aging and COVID-19. Participants will receive either Mitoquinone or a placebo to evaluate the effectiveness of this treatment in improving symptoms associated with long-COVID, such as fatigue and cognitive deficits. The study will assess the long-term health impacts of COVID-19 and provide evidence-based recommendations for rehabilitation.
Who should consider this trial
Good fit: Ideal candidates for this study are Veterans aged 50 and older who are experiencing long-COVID symptoms and are 3-12 months post-COVID-19 diagnosis.
Not a fit: Patients with severe comorbid conditions, such as unstable coronary artery disease or severe COPD, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly improve the quality of life and health outcomes for older Veterans recovering from long-COVID.
How similar studies have performed: While there is ongoing research into long-COVID rehabilitation, this specific approach targeting vascular endothelial function with Mito-Q supplementation is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 50 years of age or greater * Long-COVID and COVID-recovered patients must have SARS-CoV-19 positive test near the time of COVID-19 diagnosis * Long-COVID and COVID-recovered patients must be 3-12 months post-initial COVID-19 diagnosis * Ability to sign informed consent Exclusion Criteria: * BMI \>45 kg/m2 * Unstable (\<6 months) or severe coronary artery disease (CAD-RADS score = 4A), peripheral artery disease (Ankle Brachial Index \<0.40), cerebrovascular disease (identified by previous stroke in last 12 months), severe COPD (=Stage III), uncontrolled hypertension (\>160/100 mmHg), chronic kidney disease requiring dialysis, severe renal insufficiency (creatinine clearance \<30 by the Cockcroft-Gault formula), Alzheimer's disease, dementia * Orthopedic limitations that would prohibit exercise * \[Current smokers and individuals that stopped smoking in the last 10 years\] * Already taking Mito-Q or unwilling to cease dietary supplements for participation * Any other condition or event considered exclusionary by the PIs or a physician
Where this trial is running
Salt Lake City, Utah
- VA Salt Lake City Health Care System, Salt Lake City, UT — Salt Lake City, Utah, United States (Recruiting)
Study contacts
- Principal investigator: Joel Douglas Trinity, PhD — VA Salt Lake City Health Care System, Salt Lake City, UT
- Study coordinator: Joel D Trinity, PhD
- Email: Joel.Trinity@va.gov
- Phone: (801) 582-1565
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.